Cohen C - Search Results

1

Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice.

Cohen C, Perrault G, Sanger DJ. Cohen C, et al. Neuropharmacology. 1997 Aug;36(8):1099-108. doi: 10.1016/s0028-3908(97)00100-7. Neuropharmacology. 1997. PMID: 9294975

2

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Cohen C, Perrault G, Griebel G, Soubrié P. Cohen C, et al. Neuropsychopharmacology. 2005 Jan;30(1):145-55. doi: 10.1038/sj.npp.1300541. Neuropsychopharmacology. 2005. PMID: 15292905

3

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.

Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B. Boulay D, et al. Among authors: cohen c. Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24. Pharmacol Biochem Behav. 2008. PMID: 18621075

4

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stemmelin J, et al. Among authors: cohen c. Neuropsychopharmacology. 2008 Feb;33(3):574-87. doi: 10.1038/sj.npp.1301424. Epub 2007 Apr 25. Neuropsychopharmacology. 2008. PMID: 17460614

5

SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. Griebel G, et al. Among authors: cohen c. CNS Drug Rev. 2003 Spring;9(1):3-20. doi: 10.1111/j.1527-3458.2003.tb00241.x. CNS Drug Rev. 2003. PMID: 12595909 Free PMC article. Review.

6

CB1 receptor antagonists for the treatment of nicotine addiction.

Cohen C, Kodas E, Griebel G. Cohen C, et al. Pharmacol Biochem Behav. 2005 Jun;81(2):387-95. doi: 10.1016/j.pbb.2005.01.024. Pharmacol Biochem Behav. 2005. PMID: 15935455 Review.

7

Effects of dihydropyridine Ca2+ channel blockers on the discriminative stimulus and the motor impairing effects of (+/-)-Bay K 8644.

Cohen C, Perrault G, Sanger DJ. Cohen C, et al. Eur J Pharmacol. 1997 Oct 8;336(2-3):113-21. doi: 10.1016/s0014-2999(97)01240-5. Eur J Pharmacol. 1997. PMID: 9384222

8

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.

Salomé N, Stemmelin J, Cohen C, Griebel G. Salomé N, et al. Among authors: cohen c. Pharmacol Biochem Behav. 2006 Apr;83(4):533-9. doi: 10.1016/j.pbb.2006.03.013. Epub 2006 Apr 19. Pharmacol Biochem Behav. 2006. PMID: 16624395

9

SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. Cohen C, et al. Behav Pharmacol. 2002 Sep;13(5-6):451-63. doi: 10.1097/00008877-200209000-00018. Behav Pharmacol. 2002. PMID: 12394421

10

The preclinical pharmacologic profile of tiapride.

Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R. Scatton B, et al. Among authors: cohen c. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. doi: 10.1016/s0924-9338(00)00526-5. Eur Psychiatry. 2001. PMID: 11520476

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results